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Background:Many individuals rely on family and friends to provide care outside of the formal healthcare sector. The need for
caring is driven by many factors, including government policies toward health and social care, and increased prevalence of
chronic and comorbid conditions. Informal care may give rise to “spillover” effects from the health of a cared-for individual to
the health of carers. Spillover effects are rarely reﬂected in economic evaluations, in spite of growing research interest in this
area, and recommendations from bodies such as the National Institute for Health and Care Excellence (NICE) and the Second
Panel on Cost-Effectiveness that effects of this type be included in cost-effectiveness analysis.
Objective: We explore the positive and normative issues to which the inclusion of carer spillover effects in economic eval-
uation may give rise and how future research might begin to address these challenges.
Results: Positive challenges include the identiﬁcation of causal rather than coincidental impacts on carers, selection into
caring, and the measurement and treatment of spillover effects. The normative issues are related to these challenges, and
particularly include impacts on equity, and spillovers that improve rather than reduce the health of carers.
Conclusions: We argue that challenges including spillover effects in economic evaluation are considerable. Avenues for future
research and possible solutions to these challenges include a re-orientation of analytic perspectives so that the impacts of
caring on carers are accounted for where appropriate, and the design of studies to collect robust evidence to inform
debate and guidance development in this area.
Keywords: carers, economic evaluation, equity, spillover effects
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Changes in the health of an individual may have profound
consequences for family, friends, and others. One important and
frequently encountered consequence is the need for informal
caregiving by family and friends. We deﬁne informal caregiving as
unpaid support and assistance to an individual living with ill-
nesses or disabilities that may be chronic or acute1 and that is
above what might normally be expected in the relationship con-
cerned.2,3 By contrast, formal care comprises remunerated support
provided by professional caregivers working in the health sector.4
Many individuals rely on informal caregiving, estimates of the
monetary value of which are similar to the value of all formal
care.5-7 The need for caring is driven by a number of factors,
including aging populations living with morbidity,8,9 changes in
family composition,10 government policy toward health and socialss correspondence to: Padraig Dixon, DPhil, Population Health Sciences, Brist
, England, UK. Email: padraig.dixon@bristol.ac.uk
15 - see front matter Copyright ª 2019, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/b
doi.org/10.1016/j.jval.2018.10.010care,11 and an increased prevalence of chronic and comorbid
conditions.12 Informal care may give rise to “spillover” effects on
carers arising from the health or circumstances of a cared-for in-
dividual or patient. Population-level healthcare decisions should
account for the opportunity costs borne by unidentiﬁed fellow
citizens,13 and scrutiny of these effects and their implications for
resource allocation is merited.
The possibility of considering spillover effects in cost-
effectiveness analyses conducted from a societal perspective was
explored in 1996 by the inﬂuential “Panel on Cost-Effectiveness in
Health and Medicine.”14 The panel suggested that sensitivity
analysis be undertaken to measure the consequences of spillover
effects on caregiver quality of life. The subsequent 2016 Panel
report15 proposed that such effects, if material, be included in
analyses from the societal perspective: “The scope of a study
should be deﬁned broadly enough to encompass the full range ofol Medical School, Oakﬁeld House, Oakﬁeld Grove, University of Bristol, Bristol,
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
550 VALUE IN HEALTH MAY 2019groups of people affected by the intervention and all important
consequences.”16 The National Institute of Health and Care
Excellence (NICE) guidelines for the health technology appraisal17
recommended the inclusion of “direct health effects, whether for
patients or other people” in their reference case for analyses
conducted from health system perspectives; nevertheless, no
practical guidance was made available to give effect to this
recommendation.
Despite increasing methodological and applied work (eg, Al-
Janabi et al18), spillover effects are infrequently included in eco-
nomic evaluation,19 rare instances of inﬂuential examples (eg,
Christensen et al20) notwithstanding. We build on recent work in
this area by exploring the positive and normative issues to which
inclusion in economic evaluation of carer spillover effects may
give rise and identify areas for future research, the need for which
was noted by Neumann et al.15
We refer to individuals living with illnesses or disabilities who
are the targeted beneﬁciaries of interventions subject to economic
evaluation as patients, and those providing informal care (in the
sense deﬁned above) to these patients as carers. We do not
consider health spillover effects owing to mechanisms such as the
transmission of infectious diseases arising from vaccination (see
Benjamin-Chung et al21 for a discussion of some of these issues).
Finally, the spillovers with which we are concerned here relate
only to carer health, rather than measures of welfare other than
health, such as carer consumption, employment, or leisure. This
approach—of focusing on health as the primary object of interest—
differs from welfarist analyses of spillover effects, such as that of
Basu and Meltzer.22 Policy evaluation in which the welfare of in-
dividuals is assessed in terms of the self-assessed, subjective,
rational, and consistent utilities that these individuals obtain from
consumption may be described as welfarist.23,24 Cost-beneﬁt
analysis is an example of this approach.
The approach of this article is more consistent with extra-
welfarist approaches such as cost-utility analysis, which supple-
ment the individual utilities of the welfarist approach with other
“nonutility” objects that are relevant to the individual and which
should be accounted for in comparing individual outcomes.
Interpersonal comparisons of well-being may be made on the
basis of these “extra” dimensions of individual well-being.25,26
For our purposes, we do not describe what ought to be
included when comparing outcomes, but simply claim that
including spillover effects does not appear to be in obvious conﬂict
with extra-welfarism. It seems plausible that an extra welfarist
decision maker, including under a social decision-making inter-
pretation of extra welfarism,27 with objectives other than seeking
Paretian welfare improvements,28 could consider spillover effects
in seeking to optimize some health-related objective function.
Positive Issues
In this section we describe the conditions necessary for spill-
overs to be accounted for in a consistent manner. We assume that
any analysis proceeds from an analysis of the opportunity costs to
which spillover effects may give rise.
Causal Effects
Analyses of spillovers may be confounded by concurrent but
unrelated health changes in the carer, an issue likely to be
particularly acute in older, frailer, and comorbid carer populations.
Much recent research has relied on cross-sectional study designs
that mean it is not possible to establish the temporality of the
relationship.In one recent overview of literature, Tilford and Payakachat29
did not identify any studies that included family spillover effects
with the framework of prospective analysis of randomized
controlled trials (RCTs). Tilford et al30 studied autism-related sleep
disorders and quality-of-life outcomes for primary caregivers and
concluded that “Our results are not intended to suggest a causal
relationship between sleep and depression, as we recognize the
limitations of cross-sectional data and the potential for relation-
ships to be recursive.” Adjustment using multivariable regression,
or similar techniques such as matching, cannot eliminate the
possibility of residual confounding or collider bias (discussed
further below).
If study designs are not prospective, and particularly if they are
not based on randomized controlled trials, it will be difﬁcult to
establish if an observed change in carer health is due to a spillover
effect, and the observed association may not be causal. This could
lead to a type of double counting (or undercounting) in which a
combined estimate of health change (patient plus carer via a
spillover effect) is estimated with error; for example, a cross-
sectional study design that cannot identify temporal changes
might estimate spillover effects by counting changes in carer
health that were unconnected to caring and are therefore incor-
rectly characterized as a spillover.
Moreover, measuring carer status at one point in time, such as
in the period immediately after a change in caring status, may be
misleading. Carers need not passively accept a decrement to
health as an unavoidable consequence of a change in caring status.
Any impairment of carer health may in some cases be reduced or
eliminated relatively quickly in some cases after the receipt of
effective treatment directed at the carer, and the point of obser-
vation of these effects is therefore a critical issue in study design.
Selection Bias
Selection bias is likely to be important in understanding
spillover effects. This does not refer to the idea of representa-
tiveness but instead to the possibility that, in selected populations,
a relationship can exist between an outcome (such as carer health)
and an exposure (becoming a carer) when the basis of selecting
the study population is itself a potential outcome of both caring
and carer health and is conditioned on in analysis. This is some-
times known as collider bias.31 This could arise from sampling
designs that recruited or solicited information only from, for
example, a support group for carers who self-report health im-
pacts from caring, which may create an association between car-
ing and carer health when none exist in truth.32
Sterne et al33 suggest a means of evaluating bias in non-
randomized studies: to view such studies against the ideal, hy-
pothetical, and potentially unethical randomized trial, conducted
on the same group of individuals to answer the question of in-
terest. The ideal hypothetical experiment in the present context
would be to randomize individuals into different caring statuses,
which would ensure (in expectation) that their assets, capacity to
care, and other covariates were balanced and the effect of caring
on outcomes such as carer health could be assessed without bias.
This hypothetical experiment is indeed impractical and unethical
but reveals the challenge faced by empirical research in this ﬁeld,
and the types of bias that are likely to arise in observational
studies, because carers are known to differ along a variety of
baseline dimensions that will inﬂuence the apparent but not
necessarily the actual association between caring and carer
health.1,4,34
The challenges of identifying the causal effects of health con-
ditions and handling selection bias are similar whether a patient-
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all manner of study designs is potentially relevant, although
robust randomized study designs are likely to be preferred where
feasible. Careful analysis is required to detect spillover effects that
are relevant to the context under investigation, given the possi-
bilities for mistaking coincidental for causal impacts, the risks of
double counting, and the relative lack of evidence on carer health
impacts and spillover effects generally.
Beneﬁcial Impacts on Carer Health
Spillover effects may improve carer health.1,35-40 This associa-
tion, if causal, is consistent with altruistic motivations for
providing care (eg, Becker41) and with ﬁndings40,42 that the
overall level (or perceived level) of caregiving burden may inﬂu-
ence the extent of spillover effects. It is not obvious that there are
grounds for excluding positive (health improving) spillover effects
from consideration in economic evaluations, although the uses to
which those data might be put continues to be the subject of
debate.
Economic evaluations are premised on analysis of mean effects
in the population concerned because it is generally these effects
that are relevant to a decision maker. The mean impact of caring
on carers may have a material effect on the probability
cost-effectiveness when account is taken of heterogeneity in carer
responses, notwithstanding the possibility that caring re-
sponsibilities have nuanced effects that depend on circumstances
and may, on balance, reduce average carer health.38 These heter-
ogenous effects also have implications for the design and sensi-
tivity of instruments used to measure carer health and wellbeing,
a point we consider in the “Other Issues” section below.Identiﬁcation of Carer Networks
Identiﬁcation of carer networks is a necessary step in incor-
porating spillover effects. Gold et al14 note in the context of eco-
nomic evaluations conducted from the societal perspective: “In
the extreme, through altruism, entire communities can be
affected.”
Ride43 discusses a natural network that arises in the context of
postnatal depression—that formed between mother and child. Al-
Janabi et al44 develop a framework for including spillovers in
“family networks”, where the term “family” is “used loosely to
describe the close network of individuals around the patient.”
Canaway et al45 describe an outcome measure for use in economic
evaluation that captures care beneﬁts to those close to the dying.
The present article is concerned with the slightly narrower
circumstance in which the identity of the carer or carers con-
cerned is unambiguous. Nevertheless, at least one further positive
challenge remains once all relevant carer health impacts have
been deﬁned: the comparison of interventions that have been
evaluated using carer networks of differing composition.
For example, an evaluation of an intervention could include
only a primary carer, or it could include each and every carer
involved with providing care to a particular individual. Discretion
to deﬁne the “depth” of these carer networks—even when strictly
limited to carers (as deﬁned) rather than wider networks of family
and friends—will complicate comparisons of these effects in
different disease areas or for different interventions for the same
disease because the extent of any health impact will depend on
the depth of the spillover network analyzed. This may also give
rise to equity issues—if attention is focused on the widest possible
network of informal caregivers, it is possible that more health
impacts will be calculated for some patients and not others, even
if the patient-only and primary caregiver effects are identical.These types of normative complications are discussed further in
the “Normative Issues” section below.
Other Issues
The importance to economic evaluation of heterogeneous carer
impacts has implications for the design and sensitivity of in-
struments used to measure carer health.46,47 Wittenberg and
Prosser48 argue that “The combination of positive and negative
effects that is inherent to spillover of illness underscores the need
for the measurement instrument used to include the correct
deﬁnition of domains to capture this effect.”
In a sense, these are familiar arguments concerning instrument
suitability, although the challenges may be more severe when
considering that health impacts on carers may be a fraction of the
impact on the patient.49 Al-Janabi et al50 report the difﬁculties
involved in predicting carer health status from the health of their
cared-for patients. Canaway51 describes a number of approaches
to understanding and measuring carer impacts in the context of
end of life care. Bhadhuri et al52 ﬁnd that both the EuroQol,
5-dimension, ﬁve level53 instrument and Short-Form, Six-dimen-
sion54 instrument have a reasonable degree of validity for
measuring health spillovers.
In this context of measuring impacts, it is important to
consider the likely quantitative signiﬁcance of spillover effects in
different circumstances. Funding and implementing robust study
designs in this area will be challenging, but as Al-Janabi et al55
argue: “There is both a moral and a practical imperative to
consider carers in healthcare decisions given the vital role they
have in supporting the health system.” A more direct focus on
carers as the central object of investigation is likely to be desirable
in some cases, but in others justiﬁcation as to why carer impacts
ought not be included may be appropriate.48
A further challenge is accounting for changes in caring status.
For example, a carer may change their place of residence, decide to
stop caring, require care themselves, or die.56 If a prospective
evaluation of an intervention determined it to be cost-effective
when accounting for spillover effects, should the conclusion of
this evaluation change in light of changes in carer status? This is
both a positive and a normative challenge. The positive challenge
is the need to measure and reﬂect these changes in an economic
evaluation when the data concerned are likely to reﬂect an
observational rather than an interventional study design. The
normative issue is of a type explored in more detail in “Normative
Issues” section below: if caring status is more likely to change for
one group of carers than another, should such differences between
compared groups be treated in the same way?
Finally, a fundamental tenet of economic evaluation is that
meaningful conclusions depend on interventions being compared
to the best-available comparator technology.57 The inclusion of
spillovers in economic evaluation presents a subtle complication
to the selection of relevant comparators, which may require the
evaluation of a technology other than the one targeted at the
patient who would otherwise be the focus of the cost-
effectiveness analysis. What is the best available comparator
technology when effects on both patient and carer health are
included? If spillover effects are incidental impacts on third
parties, is there a case for considering comparators other than the
one most appropriate to the patient, even if to do so may reduce
the aggregate of patient and carer health?Normative Issues
None of the discussion of positive effects can, on its own terms,
inform a decision as to whether spillover effects ought to be
Table 1. Choice of the appropriate comparator in accounting for spillovers
Perspective
Patient-only perspective Patient and carer
“spillover” perspective
Scenario A—a single intervention compared to usual care
Incremental cost of the intervention £2100 £2100
Incremental patient QALYs 0.1 0.1
Incremental carer QALYs — 0.01
Total incremental QALYs 0.1 0.11
Cost-effectiveness threshold £20 000 per QALY £20 000 per QALY
Incremental cost-effectiveness ratio £21 000 £19 091
Cost-effective? No Yes
Scenario B—separate patient and carer interventions compared to usual care
Incremental cost of patient intervention £1900 £1900
Incremental cost of carer intervention — £300
Total incremental cost of the
interventions
£1900 £2200
Incremental patient QALYs 0.09 0.09
Incremental carer QALYs — 0.03
Total incremental QALYs 0.09 0.12
Cost-effectiveness threshold £20 000 per QALY £20 000 per QALY
Incremental cost-effectiveness ratio £21 111 £18 333
Cost-effective? No Yes
QALYs, quality-adjusted life years.
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sues to which including spillover effects in economic evaluation
may give rise. In this section, we focus on two normative issues
that seem particularly consequential. First, we consider the impact
on equity in relation to resource allocation decisions. Second, we
consider maximizing population health in the presence of
spillovers.
We consider the implications of each issue against principles
sometimes used (eg, Cookson and Dolan58 and Persad et al59) to
characterize the justice of healthcare resource allocations: egali-
tarianism (equal treatment), beneﬁt to the worst-off (Rawlsian-
type approaches), need (allocation according to individual need),
and maximization (maximizing aggregate population health). In
doing so, we do not comment on the desirability of each principle
of justice per se, nor do we expect that any system of allocation
would perfectly accord with accepted interpretations of these
principles, just as existing systems of healthcare resource alloca-
tion do not. The exercise is intended to characterize normative
issues that merit scrutiny in this context.
Equity
Accounting for spillover in economic evaluation may challenge
equity because care may well be directed at patients with carer
and family networks and away from those without. Basu and
Meltzer22 ask: “Do we want to value the health of married people
more than that of unmarried people? What about people who
have few or many children or few or many friends?”
This is an example of what Culyer and Bombard60 describe
“red ﬂags” for considerations of equity in the context of tech-
nology assessment, being a behavior and circumstances that
“could, at least in principle, disadvantage some people relative to
others.” Speciﬁcally, accounting for carers may amount to treating
citizen quality adjusted life years (QALYs) equally, but not patient
QALYs equally. By citizens we mean everyone in society; the in-
clusion of spillovers in economic evaluation would therefore
represent a departure from the patient-centered health system
that has otherwise been the foundation of healthcare in countriessuch as the United Kingdom. This would generally not be
consistent—when viewed from the patient’s perspective—with
egalitarianism, allocation according to need, and the welfare of
the worst-off individual. It may be consistent with maximizing
overall societal QALYs of all citizens, a point we return to in the
next section.
As Basu and Meltzer22 and Al-Janabi49 note, not including such
claims is itself a decision that may conﬂict with patient concerns
that are neglected in conventional cost-effectiveness analyses.
This objection could be characterized as an instance of the trade-
off between maximizing aggregate health and delivering accept-
able health equity.61 The consequences for equity are real but
require empirical evidence as to their magnitude and channels of
operation. For example, when spillovers are included then, for
example, shallower networks of available carers among the old
(eg, Schnittker62) could give rise to a transfer of resources to the
young. The complications of selection into caring, such as ﬁnancial
capacity to enter full-time caring, also have a bearing on these
arguments.
Including spillovers may therefore have an adverse impact on
equity, particularly for those with limited access to informal care.
Nevertheless, including spillovers may support maximization of
QALYs across the population, even if this is not consistent with
maximizing patient QALYs. We consider maximization issues in
the next section.
Spillovers, Heterogeneity, and a Maximizing Approach to
Justice
Maximizing aggregate health in the presence of spillovers may
reduce the health of patients. Consider the following example. An
elderly individual, receiving informal care, develops a life-
threatening health condition. An intervention is available that
will extend this individual’s life but with the consequence of se-
vere disability and lifetime care requirements. The new post-
intervention health state then permanently reduces carer self-
assessed health because of spillover effects that cannot be
ameliorated.
NOTIONS OF “VALUE” IN HEALTHCARE 553Accounting for both increases and decreases in carer health is
required by spillover logic. It is conceivable that a crude “patient
plus carer” QALY maximization decision may be to refuse to pro-
vide care to this patient, which would be the case if the inter-
vention were only just cost-effective when the patient’s
circumstances alone were considered, but not cost-effective when
the carer’s health was additionally considered. Is the extra-
welfarist decision-maker justiﬁed in denying care to the patient?
If the answer to this question is no, accounting for spillover effects
is not consistent with a health maximizing approach to resource
allocation.
This reﬂects a familiar objection (Posner’s63 “moral
monstrousness”) to act utilitarianism, in that no action and no
infringement of individual liberty is impermissible provided that
the aggregate utility, happiness, or (in this example) health is
maximized as a consequence of that action. This issue arises in
several ways once spillover effects are admitted into economic
evaluation. Parents transfer more resources to their adult children
than vice versa.5,64 The resentment by carers of frail elderly pa-
tients is associated with carer anxiety and depression.65 Never-
theless, it is problematic to deny an effective treatment to a
patient simply because so doing might improve the health of the
carer.
In the example above, cost-effectiveness fails because of the
impact on effectiveness, in which the aggregate of carer and
patient health is less than patient health alone. This is not to
deny the possibility that a patient without an informal carer
may require expensive formal care, and this formal care may
itself not be cost-effective because of the impact on costs, as
opposed to effectiveness in the previous example. For example,
Neumann et al66 estimated the cost-effectiveness of an Alz-
heimer’s disease drug to be more favorable when informal
caregiving costs were included because informal caregiving
avoided expensive nursing home costs. Both possibilities
require recognition and appropriate handling in cost-
effectiveness analyses.
Consider Table 1, in which an alternative course of action raises
rather than reduces carer health. Scenario A describes an inter-
vention that is not cost-effective (at a particular cost-effectiveness
threshold) when only patient outcomes are considered, but which
is cost-effective when spillover carer QALYs are included. We
ignore uncertainty in this simple example.
In scenario B, the same patient-carer dyad is involved, but two
separate interventions (one directed at the patient, and one at the
carer) are considered. In each scenario, the patient-only perspec-
tive is not cost-effective. In scenario B, aggregate costs and QALYs
are higher, but the two interventions when considered together
are nevertheless more cost-effective than the original intervention
targeted at the patient. Nevertheless, in scenario B, the patient is
worse off in QALY terms than in scenario A, yet aggregate QALYs
are higher. Resources are used more efﬁciently because the in-
cremental cost-effectiveness ratio in the combined patient/carer
perspective is lower than that in scenario A. Again, a QALY-
maximizing decision maker would be inclined to accept a reduc-
tion in patient health, but this may conﬂict with priority to the
worst-off.
The artiﬁcial parameters of this example were selected to
illustrate the point, and empirical evidence is required. The con-
trolling mind of an extra-welfarist decision maker must account
for these types of effect in maximizing population health, a
consequence of which is that the patient may be worse off under
consideration of spillover effects than without, even if dyadic
patient-carer health is higher, and even if aggregate societal health
is higher.Conclusions
Spillover effects occupy a unique but uneasy position in eco-
nomic evaluation. They feature in one form or another in impor-
tant guidelines and reference cases but are infrequently included
in economic evaluations. An important task in future research will
be to quantify the equity impacts of spillovers, particularly
because equity in general is arguably an underdeveloped element
in economic evaluation and technology appraisal.67 The accept-
ability of equity impacts could be approached and characterized
using analytic approaches, including methods recently described
in, for example, Asaria et al68 and Cookson et al.69 Further high-
quality evidence from robust study designs is also needed. There
seems to be clear need for further guidance in this area, not only
because of the methodological challenges issues noted, but also
because the salience of spillover effects is likely to increase in the
context of aging and comorbid populations, changes in family
composition, and new healthcare technologies.Acknowledgments
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